Fixed-combination products in the management of acne vulgaris

Cutis

Volumn 85, Issue 3, 2010, Pages 160-167

  Gold, Linda Stein ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BENZOYL PEROXIDE; DERMATOLOGICAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOID;

ACNE VULGARIS; DRUG COMBINATION; HUMAN; PATHOLOGY; REVIEW;

ACNE VULGARIS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOYL PEROXIDE; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; HUMANS; RETINOIDS;

EID: 77952297966     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Pawin H, Beylot C, Chivot M, et al. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol. 2004;14:4-12.
2. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(suppl 3):S200-S210.
3. Bataille V, Snieder H, MacGregor AJ, et al. The influence of genetics and environmental factors in the pathogenesis of acne: a twin study of acne in women. J Invest Dermatol. 2002;119:1317-1322.
4. Goulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol. 1999;141:297-300.
5. Cordain L, Lindeberg S, Hurtado M, et al. Acne vulgaris: a disease of Western civilization. Arch Dermatol. 2002;138:1584-1590.
6. Kelly AP. Acne and related disorders. In: Sams WMJ, Lynch PJ, eds. Principles and Practice of Dermatology. 2nd ed. New York, NY: Churchill Livingstone; 1996: 801-818.
7. Niemeier V, Kupfer J, Demmelbauer-Ebner M, et al. Coping with acne vulgaris. evaluation of the chronic skin disorder questionnaire in patients with acne. Dermatology. 1998;196:108-115.
8. Webster GF. Acne and rosacea. Med Clin North Am. 1998;82:1145-1154.
9. Gollnick H, Orfanos CE. Clinical assessment of acne. In: Cunliffe WJ, ed. Acne. Stuttgart, Germany: Hippokrates; 1993:155-222.
10. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology. 1998;196:119-125.
11. Thiboutot D. New treatments and therapeutic strategies for acne. Arch Fam Med. 2000;9:179-187.
12. Bárány E, Lindberg M, Lodén M. Biophysical characterization of skin damage and recovery after exposure to different surfactants. Contact Dermatitis. 1999;40:98-103.
13. Effendy I, Maibach HI. Surfactants and experimental irritant contact dermatitis. Contact Dermatitis. 1995;33:217-225.
14. Leyden J, Kaidbey K, Levy SF. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. Am J Clin Dermatol. 2001;2:263-266.
15. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol. 1997;37:590-595.
16. Cunliffe WJ, Holland KT, Bojar R, et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24:1117-1133.
17. Baldwin HE. Tricks for improving compliance with acne therapy. Dermatol Ther. 2006;19:224-236.
18. Warner GT, Plosker GL. Clindamycin/benzoyl peroxide gel: a review of its use in the management of acne. Am J Clin Dermatol. 2002;3:349-360.
19. Leyden JJ, Berger RS, Dunlap FE, et al. Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatment of acne vulgaris. Am J Clin Dermatol. 2001;2:33-39.
20. Burkhart CG, Burkhart CN. Antibacterial properties of benzoyl peroxide in aerobic and anaerobic conditions. Int J Dermatol. 2006;45:1373-1374.
21. Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne treatment. Pediatrics. 2006;118:1188-1199.
22. Leyden JJ, Hickman JG, Jarratt MT, et al. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg. 2001;5:37-42.
23. Fagundes DS, Fraser JM, Klauda HC. Difference in the irritation potential and cosmetic acceptability of two combination topical acne gels-combined results of two comparative studies. Today's Ther Trends. 2003;21: 269-276.
24. Koo J. How do you foster medication adherence for better acne vulgaris management? Skinmed. 2003;2:229-233.
25. Eady EA, Farmery MR, Ross JL, et al. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol. 1994;131:331-336.
26. Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol. 1996;134:107-113.
27. Gupta AK, Lynde CW, Kunynetz RA, et al. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg. 2003;7:31-37.
28. Ellis CN, Leyden J, Katz HI, et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis. 2001;67(suppl 2):13-20.
29. Leyden JJ. Effect of topical benzoyl peroxide/clindamycin versus topical clindamycin and vehicle in the reduction of Propionibacterium acnes. Cutis. 2002;69:475-480.
30. Wolf JE Jr, Kaplan D, Kraus SJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol. 2003;49(suppl 3):S211-S217.
31. Mills OH Jr, Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol. 1978;58:555-557.
32. Franz TJ, Lehman PF. Systemic absorption of retinoic acid. Cutan Ocul Toxicol. 1989;8:517-524.
33. Rietschel RL, Duncan SH. Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol. 1983;22:41-43.
34. Richter JR, Bousema MT, De Boulle KLVM, et al. Efficacy of a fixed clindamycin phosphate 1.2%, tretinoin 0.025% gel formulation (Velac) in the topical control of facial acne lesions. J Dermatol Treat. 1998;9:81-90.
35. Korting HC, Braun-Falco O. Efficacy and tolerability of combined topical treatment of acne vulgaris with tretinoin and erythromycin in general practice. Drugs Exp Clin Res. 1989;15:447-451.
36. Hurwitz S. The combined effect of vitamin A acid and benzoyl peroxide in the treatment of acne. Cutis. 1976;17:585-590.
37. Mills OH Jr, Kligman AM, Pochi P, et al. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;25:664-667.
38. Kligman AM, Leyden JJ, Stewart R. New uses for benzoyl peroxide: a broad-spectrum antimicrobial agent. Int J Dermatol. 1977;16:413-417.
39. Caron D, Sorba V, Clucas A, et al. Skin tolerance of adapalene 0.1% gel in combination with other topical antiacne treatments. J Am Acad Dermatol. 1997;36 (6, pt 2):S113-S115.
40. Thiboutot DM, Weiss J, Bucko A, et al; Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007;57:791-799.
41. Pariser DM, Westmoreland P, Morris A, et al. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6: 899-905.
42. Andres P, Pernin C, Poncet M. Adapalene-benzoyl peroxide once-daily, fixed-dose combination gel for the treatment of acne vulgaris: a randomized, bilateral (splitface), dose-assessment study of cutaneous tolerability in healthy participants. Cutis. 2008;81:278-284.
43. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis. 2007;79(suppl 6):9-25.
44. Tanghetti E, Abramovits W, Solomon B, et al. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, doubleblind, randomized parallel-group trial. J Drugs Dermatol. 2006;5:256-261.
45. Katsambas AD. Why and when the treatment of acne fails. what to do. Dermatology. 1998;196:158-161.
46. Flanders PA, McNamara JR. Enhancing acne medication compliance: a comparison of strategies. Behav Res Ther. 1985;23:225-227.
47. Draelos ZK. Patient compliance: enhancing clinician abilities and strategies. J Am Acad Dermatol. 1995;32 (5, pt 3):S42-S48.
48. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884.
49. [49] Kellett N, West F, Finlay AY. Conjoint analysis: a novel, rigorous tool for determining patient preferences for opical antibiotic treatment for acne. a randomised controlled trial. Br J Dermatol. 2006;154:524-532.
50. Bikowski JB. Treatment selection and patient education tips to boost compliance in acne therapy. Pract Dermatol. 2005;46-51.
51. Rossi P, Wiechers JW, Kelly C. Improved delivery and efficacy with dimethyl isosorbide. Cosmet Toiletries. 2005;120:107-111.
52. Bucks D, Sarpotdar P, Yu K, et al. The development and optimization of a fixed combination of clindamycin and benzoyl peroxide aqueous gel. J Drugs Dermatol. 2009;8:634-638.
53. Thiboutot D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol. 2008;59:792-800.
54. Gold MH. A new once-daily, optimized, fixed combination of clindamycin phosphate 1.2% and low-concentration benzoyl peroxide 2.5% gel for the treatment of moderateto-severe acne. J Clin Aesthetic Dermatol. 2009;2:44-48.